STC 15
Alternative Names: STC-15Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Evotec SE; Storm Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action METTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (PO)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in United Kingdom (PO)
- 11 Nov 2024 Efficacy, adverse events, pharmacodynamics data from a phase I trial in Solid tumours released by STORM Therapeutics